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Inhibition of 5a-reductases impairs androgen and glucocorticoid metabolism and induces insulin
resistance in humans and rodents. The contribution of hepatic glucocorticoids to these adverse
metabolic changes was assessed using a liver-selective glucocorticoid receptor (GR) antagonist,
A-348441. Mice lacking 5a-reductase 1 (5aR1-KO) and their littermate controls were studied during
consumption of a high-fat diet, with or without A-348441(120 mg/kg/d). Male C57BL/6 mice (age,
12 weeks) receiving dutasteride (1.8 mg/kg/d)) or vehicle with consumption of a high-fat diet, with
or without A-348441, were also studied. In the 5aR1-KO mice, hepatic GR antagonism improved
diet-induced insulin resistance but not more than that of the controls. Liver steatosis was not
affected by hepatic GR antagonism in either 5aR1KOmice or littermate controls. In a second model
of 5a-reductase inhibition using dutasteride and hepatic GR antagonismwith A-348441 attenuated
the excess weight gain resulting from dutasteride (mean 6 SEM, 7.03 6 0.5 vs 2.13 6 0.4 g;
dutasteride vs dutasteride plus A-348441; P, 0.05) and normalized the associated hyperinsulinemia
after glucose challenge (area under the curve, 235.9 6 17 vs 329.3 6 16 vs 198.4 6 25 ng/mL/min;
high fat vs high fat plus dutasteride vs high fat plus dutasteride plus A-348441, respectively; P ,
0.05). However, A-348441 again did not reverse dutasteride-induced liver steatosis. Thus, overall
hepatic GR antagonism improved the insulin resistance but not the steatosis induced by a high-fat
diet. Moreover, it attenuated the excessive insulin resistance caused by pharmacological inhibition
of 5a-reductases but not genetic disruption of 5aR1. The use of dutasteride might increase the risk
of type 2 diabetes mellitus and reduced exposure to glucocorticoids might be beneficial. (Endo-
crinology 160: 2061–2073, 2019)
The consequences of glucocorticoid excess have beenwell established, with links to metabolic disease ex-
emplified by patients with Cushing syndrome. Gluco-
corticoids primarily mediate their actions through the
glucocorticoid receptor (GR), activation of which can be
regulated by prereceptor metabolism within tissues. For
example, 11b-hydroxysteroid dehydrogenase types 1
and 2 have been shown to modulate GR and mineral-
ocorticoid receptor activation, respectively (1, 2). The
potential role of other enzymes such as the 5a-reductases
(5aRs), which are responsible for the rate-limiting step in
glucocorticoid metabolism in modifying GR activation,
has been less clearly established.
Two main isozymes of 5aRs can metabolize many
pregnene steroids. Type 2 5aR (5aR2) is highly ex-
pressed in the male reproductive tract, where it amplifies
androgen action. In contrast, 5aR type 1 (5aR1) is most
highly expressed in the liver but also in adipose tissue and
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skeletal muscle at lower levels (3, 4). 5aR inhibitors such
as finasteride (which inhibits type 2) and dutasteride
(which inhibits both isozymes) are prescribed for many
men with prostate disease (5). A recent population-based
cohort study found the risk of developing new-onset type
2 diabetes was greater in men exposed to 5aR inhibitors
compared with those receiving tamsulosin (6). Further-
more, human studies have shown that the combined
inhibition of 5aR1 and 5aR2 (but not 5aR2 alone)
impaired insulin sensitivity and resulted in increased
hepatic fat content compared with measurements before
dutasteride treatment (7, 8). Similarly, genetic disruption
of 5aR1, but not 5aR2, in 5aR1 knockout (5aR1KO)
mice also caused hyperinsulinemia, weight gain, in-
creased hepatic triglyceride deposition, and a predispo-
sition toward irreversible liver disease (4, 9).
Given the abundance of 5aR1 in the liver and the
characterized hepatic phenotype in 5aR1KO mice and
humans receiving 5aR inhibitors, it is likely that the liver
is a crucial site of steroid accumulation after 5aR1 in-
hibition or deficiency. Although accumulation of either
androgens or glucocorticoids could be responsible for
the adverse metabolic effects, androgen accumulation
appears a less likely mechanism. Nonselective inhibition
of 5aRs in obese Zucker rats induced fatty liver in both
castrated and intact rats (4), and female 5aR1KO mice
were more susceptible to hyperinsulinemia than were
males (10). Therefore, we hypothesized that hepatic
glucocorticoid excess underpins the adverse metabolic
changes observed after 5aR1 inhibition or disruption,
driving hepatic steatosis and insulin resistance.
Systemic GR antagonism with compounds such as
mifepristone (RU486) improves insulin and glucose ho-
meostasis in ob/obmice (11); however, the site of action is
uncertain and likely multiple, with effects confounded by
compensatory hypercorticosteronemia. To test our hy-
pothesis that the metabolic phenotype in mice with dis-
ruption of 5aR1 is driven by excess glucocorticoid action
in the liver, we used the liver-selective GR antagonist,
A-348441. A-348441 is a cholic acid conjugate of the
GR antagonist RU486 (12) that selectively acts in the liver
to antagonize the GR. In leptin-deficient ob/ob mice,
A-348441 successfully improved glucose homeostasis,
without elevated circulating corticosterone (13). Using
euglycemic-hyperinsulinemic clamps, it was demonstrated
to decrease hepatic glucose output and increased insulin
sensitivity in fa/fa rats, a genetic model of obesity (13, 14),
making it a suitable model for our study.
Research Methods and Design
Chemicals were from Sigma-Aldrich (Poole, UK) and primers
from Invitrogen Life Technologies (Paisley, UK), unless
otherwise stated. All molecular biology reagents and kits were
from Qiagen (West Sussex, UK). Dutasteride was from AK
Scientific (Union City, CA), and A-348441 was a gift from
KaroBio (Huddinge, Sweden). The diets were from Research
Diets, Inc. (New Brunswick, NJ), who also prepared the custom
high-fat diets containing dutasteride and A-348441.
Animals
Male mice deficient in 5aR1 (5aR1KO; n 5 8 to 11 per
group housed 2 to 4 mice per cage at 21°C) were bred in house
by mating heterozygous mice with a mixed C57Bl6/SvEv/129
background (3, 4), with the corresponding mixed-strain wild-
type littermates used as controls. The C57BL6/J male mice were
from Harlan (Bicester, UK). The mice were studied under UK
Home Office license and had free access to drinking water and
food. The mice were culled (8:00 to 10:30 AM) by decapitation
with the trunk blood collected.
Insulin signaling analysis
The insulin signaling pathways were studied in a subset of
C57BL/6 mice. These were fasted for 4 hours (from 10:00 AM to
2:00 PM) in clean cages, and human insulin (0.75 U/kg body
weight in saline) was given via intraperitoneal injection. These
mice were culled via decapitation after 15 minutes. In all cases,
the tissues were dissected, wet weighed, and snap frozen on dry
ice or fixed in 10% formalin.
GR antagonism in 5aR1KO mice
Male 5aR1KO and corresponding littermate control mice
(n5 8 to 11 per group; age, 12 weeks) were randomly allocated
to a chow diet (11% fat, 0% sucrose; D12328); a Western style
high-fat, high-sucrose diet (HFD; 58% kcal fat, 13% kcal
sucrose; D12331) alone, or HFD containing A-348441 (120
mg/kg/d). After 9 weeks of experimental diet, the mice were
fasted for 6 hours (8:00 AM to 2:00 PM) before undergoing a
glucose tolerance test (GTT; intraperitoneal injection; 2 mg/g),
with blood taken by tail venesection at 0, 15, 30, 60, and 90
minutes. One week later, blood was taken at 8:00 AM for basal
corticosterone measurement, and 2 days later (after 10 weeks of
the experimental diet), the mice were culled as stated. A-348441
was mixed within the HFD to achieve long-term administration
without causing chronic stress that would result from repeat
injection or gavage. This was especially desirable because
disruption of 5aR1-mediated corticosterone clearance impairs
the corticosterone stress response (15).
GR antagonism after pharmacological inhibition of
5aRs with dutasteride in C57BL/6 mice
C57BL6/J male mice (n5 8 to 12 per group; age, 12 weeks)
were randomly allocated to chow diet, HFD alone, HFD con-
taining A-348441 (120 mg/kg/d), HFD plus dutasteride (1.8 mg/
kg/d), or HFD plus dutasteride plus A-348441 (same doses) for
4 weeks. GTTs were performed after 3 weeks of the experimental
diet. The mice were culled 1 week later (after 4 weeks of the
experimental diet).
Laboratory analyses
Biochemistry
Plasma hormones were measured by ELISA as follows:
corticosterone [Enzo Life Sciences, Exeter, UK; RRID:
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AB_2307314 (16)], insulin [Crystal Chem, Elk Grove Vil-
lage, IL; RRID: AB_2783626 (17)], glucose by hexokinase
assay (ThermoFisher, Loughborough, UK), triglycerides
(ThermoFisher, Hemel Hempstead, UK), and nonesterified
fatty acids (NEFAs; Zen-Bio, Research Triangle Park, NC)
spectrophotometrically. Liver triglycerides were quantified
as reported previously (18).
Quantification of mRNAs by real-time
quantitative PCR
RNA was extracted as previously described (4). mRNA
transcript abundances were quantified using real-time PCR, as
previously described, with primers and probes as detailed by
Livingstone et al. (4), McInnes et al. (19), and Nixon et al.
(20). Transcript abundances for genes of interest were nor-
malized for the mean abundance of the reference genes, Tbp,
Hprt, and Actb, the expression of which did not differ be-
tween groups.
Western blot analysis
Snap-frozen liver (;40 mg) was homogenized with a rotor
blade in ice-cold radioimmunoprecipitation assay buffer (Santa
Cruz Biotechnology, Dallas, TX). Western blots were per-
formed as previously described (19). The specific primary
antibodies used were as follows: monoclonal rabbit anti-
IRb [RRID: AB_2280448 (21)], polyclonal rabbit anti-
phosphorylated AKT (Ser473) [RRID: AB_329825 (22)],
polyclonal rabbit anti-AKT [RRID: AB_329827 (23)],
polyclonal rabbit anti-phosphorylated GSK-3b (Ser9)
[RRID: AB_331405 (24)], and monoclonal rabbit anti-
GSK-3b [RRID: AB_490890 (25)], all from Cell Signaling
Technologies (Leiden, Netherlands); polyclonal anti-rabbit GR
[RRID: AB_2155784 (26)] from Santa Cruz Biotechnology,
Inc. (Heidelberg, Germany); and monoclonal mouse anti-
b-tubulin [RRID: AB_94650 (27)], monoclonal mouse anti-
IRS1 [RRID: AB_11214300 (28)], and monoclonal mouse anti-
IRS2 [RRID: AB_10615782 (29)], all from Millipore, Ltd.
(Watford, UK). The secondary antibodies were IRDye 680RD
goat anti-rabbit IgG (H1L) [RRID: AB_10956166 (30)],
IRDye 800CW goat anti-rabbit IgG (H1L) [RRID: AB_621843
(31)], and IRDye 800CW goat anti-mouse IgG [RRID: AB_
2782997 (32)], all from LI-COR Biosciences, Ltd. (Cambridge,
UK). Phosphorylated antibodies were diluted 1:500 in BSA
(Cohn Fraction V; 5% w/v in Tris-buffered saline-Tween), and
all total protein primary antibodies were diluted 1:1000 in BSA
(5% w/v in Tris-buffered saline-Tween). Secondary antibodies
were diluted 1:10,000 in BSA when studying phosphorylation
of proteins or milk when studying total protein. Band in-
tensities were quantified using the Odyssey Imaging System
(LI-COR Biosciences, Cambridgeshire, UK). Quantification of
the proteins of interest was calculated by dividing their in-
tegrated intensity by that of the loading control (b-tubulin).
Phosphorylated proteins were normalized to their corre-
sponding bands of b-tubulin, and a ratio of (phosphorylated
protein/b-tubulin)/(total protein/b-tubulin) was used in final
analysis.
Statistical analysis
Data are presented as the mean 6 SEM, analyzed using
GraphPad Prism, version 6 (San Diego, CA), using the Student t
test or two-way ANOVA, with the Sidak post hoc test, as
appropriate. Statistical significance was considered present at
P , 0.05.
Results
Hepatic GR antagonism in mice with genetic
disruption of 5aR1
Ten weeks of the HFD was sufficient to induce an
adverse metabolic phenotype in the wild-type mice of
mixed strain (wild-type HFD) background, causing ex-
cess weight gain of ;4 g compared with that of the
mice consuming the chow diet (9.06 1.1 g vs 4.86 0.5 g;
P , 0.05). Furthermore, fasting insulin was increased
by the HFD (2.8 6 0.4 vs 2.0 6 0.3 ng/mL; P , 0.05)
without increasing the fasting glucose (HFD vs chow diet,
156.7 6 3.7 mg/dL vs 151.6 6 9.9 mg/dL). The liver
triglyceride levels were also increased by the HFD
(152.3 6 18.4 vs 36.97 6 9.4 mmol/g). The effects of
A-348441 to attenuate the metabolic changes induced
by 10 weeks of the HFD fat diet were thus studied in
5aR1KO (5aR1KO HFD) and wild-type HFD mice (the
drug was not administered to the mice receiving chow
diet). Consistent with a lack of central effects and pre-
vious data (12–14), the basal circulating corticosterone
was not altered in either genotype after administration of
A-348441 (Table 1).
The weight gain induced by the HFD was attenuated
by A-348441 in the wild-type HFD mice but not in the
5aR1KOHFD mice (Fig. 1A–1C). However, the mass of
specific adipose depots was not decreased by the drug or
different by genotype (Table 1). A-348441 lowered the
fasting glucose in the wild-type HFD mice only (Fig. 1D,
1E, and 1J) but had no effect on the overall glucose re-
sponse to a GTT (Fig. 1F). An overall effect of A-348441
was found to lower the fasting insulin level (Fig. 1G, 1H,
and 1K) and the insulin response to a GTT (Fig. 1I) in mice
of both genotypes. Similar to a previous report (4),
5aR1KO HFD mice were predisposed to develop insulin
resistance, with a trend toward a higher fasting insulin
level (Fig. 1K) and an increased insulin response to a
glucose challenge compared with wild-type HFD mice,
irrespective of the presence of A-348331 (Fig. 1I). Sur-
prisingly, the 5aR1KO HFD mice overall had lower
fasting NEFAs compared with the wild-type HFD mice
(Table 1). As a measure of adipose insulin sensitivity,
NEFA suppression during the first 15 minutes of the GTT
was measured. However, A-348441 did not influence
NEFA suppression but increased fasting NEFAs in the
wild-type HFD mice only (Table 1). Furthermore, as an-
ticipated, 5aR1KOHFDmice, overall, had higher hepatic
triglyceride levels than did their wild-type controls;
however, A-348441 did not lower hepatic or plasma tri-
glyceride levels in either genotype (Fig. 1L; Table 1).
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Liver-selective GR antagonism after dutasteride
administration in C57BL/6 mice
Mice with a C57BL/6 background are predisposed to
diet-induced obesity and were studied for a shorter pe-
riod. After only 4 weeks, a high-fat diet induced weight
gain in excess of that in the chow-fed mice (6.3 6 0.4 vs
4.0 6 0.1 g; P , 0.05), accompanied by a doubling in
fasting insulin of 2.16 0.2 vs 0.86 0.1 ng/mL (P, 0.05)
and an increase in hepatic triglyceride content (22.3 6
1.3 mmol/g vs 10.5 6 1.7 mmol/g; P , 0.05). Similar to
the littermate controls of the 5aR1KO mice (Fig. 1),
C57BL/6 mice on A-348441 had reduced weight gain
(Fig. 2A) and no changes in glucose tolerance (Fig. 2D)
but lowered insulin levels (Fig. 2G).
Successful administration of dutasteride was confirmed
by a reduction in prostate size (Table 2). Coadministration
of dutasteride with the HFD exacerbated the adverse
metabolic phenotype in C57BL/6. The body weight gain
had increased after 4 weeks comparedwith the HFD alone
(Fig. 2C), with increased adipose weight gain in the
omental depot only (Table 2). Dutasteride increased the
insulin response to a bolus of glucose during a GTT
compared with the HFD alone (Fig. 2I), as well as fasting
insulin (Fig. 2K), without altering the glucose response to
GTT or fasting glucose (Fig. 2F and 2J). Compared with
mice receiving the HFD alone, mice fed dutasteride had
increased hepatic triglyceride levels (Fig. 2L), without
differences in plasma triglycerides, fasting plasma NEFAs,
or suppression of NEFAs after the glucose challenge
(Table 2). Food intake was not measured per mouse but
on a cage basis (with limited power of n5 3), appeared to
be less in themice fed A-348441, irrespective of 5aR status
(16.9 6 0.8 vs 13.5 6 0.7 kCal per mouse daily).
In contrast with genetic deletion of 5aR1, co-
administration of A-348441 with dutasteride reduced
the excess weight gain (Fig. 2B), in parallel with reduced
expansion of visceral adipose depots and lower fasting
NEFAs (Table 2). Coadministration of A-348441
normalized the increased fasting insulin and insulin
response to GTT caused by dutasteride (Fig. 2I and 2K),
again without affecting the fasting glucose or glucose
response during a GTT (Fig. 2E and 2J). Just as in the
5aR1KO mice, coadministration of A-348441 did not
abrogate the increased liver triglyceride levels resulting
from dutasteride (Fig. 2L) nor alter NEFA suppression
(Table 2).
Effects of A-348441 on glucocorticoid and bile
acid-sensitive hepatic pathways after
administration to C57BL/6 mice
As expected, dutasteride treatment increased the ex-
pression of glucocorticoid-sensitive genes such as Per1 in
the liver (Fig. 3A). It also resulted in reduced expression
of the Sgk transcript, although Gilz was unaffected.
Liver-selective GR antagonism did not alter expression of
any of these glucocorticoid-sensitive transcripts (Fig. 3A).
Neither dutasteride nor A-348441 affected the hepatic
abundance of Nr3c1 mRNA (Fig. 3A).
Table 1. Indexes of Metabolism in Wild-Type and 5aR1KO Mice
Variable
Wild-Type KO P Value
HFD
HFD 1
A-348441 HFD
HFD
A-348441
Effect of
A-348441
Effect of
Genotype Interaction
Total weight gain, g 8.99 6 1.11 5.04 6 0.62a 8.83 6 1.37 7.61 6 0.55 , 0.01 0.21 0.16
Tissue, % body weight
Omental adipose 0.062 6 0.008 0.048 6 0.005 0.079 6 0.009 0.062 6 0.007 0.05 0.06 0.85
Liver 4.52 6 0.16 4.38 6 0.12 4.55 6 0.12 4.83 6 0.08 0.59 0.07 0.12
Gonadal adipose 3.91 6 0.32 3.33 6 0.21 4.14 6 0.36 3.83 6 0.13 0.11 0.19 0.61
Perinephric adipose 1.30 6 0.11 1.11 6 0.08 1.42 6 0.11 1.38 6 0.08 0.24 0.06 0.47
Mesenteric adipose 1.60 6 0.10 1.28 6 0.07 1.59 6 0.22 1.59 6 0.10 0.23 0.24 0.21
Subcutaneous adipose 2.08 6 0.26 1.77 6 0.12 2.54 6 0.34 2.01 6 0.18 0.08 0.14 0.65
Quadriceps muscle 1.14 6 0.06 1.19 6 0.03 1.05 6 0.05 1.23 6 0.02 0.20 0.10 0.76
Interscapular adipose 0.51 6 0.03 0.54 6 0.05 0.52 6 0.03 0.53 6 0.06 0.36 0.05 0.64
Biochemistry
Corticosterone, nM 35.2 6 2.2 37.9 6 2.1 35.9 6 3.5 38.5 6 3.3 0.10 0.45 0.82
Plasma TGA, mmol/L 2.07 6 0.20 1.79 6 0.16 2.01 6 0.20 1.87 6 0.07 0.14 0.80 0.92
Fasting NEFA, mM 1.58 6 0.12 1.91 6 0.14 1.26 6 0.08 1.38 6 0.10 0.06 , 0.01 0.40
DNEFA, mM (0–15 min
of GTT)
0.29 6 0.16 0.44 6 0.10 0.06 6 0.11 0.38 6 0.07 0.04 0.15 0.33
Mice were fed the HFD or HFD plus A-348441 diet for 10 wk.
Data presented as mean 6 SEM and compared using two-way ANOVA with Sidak post hoc tests.
Abbreviation: TGA, triglycerides.
aCodes of comparisons (P , 0.05) within same genotype: vs HFD, n 5 8 to 11 per group.
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Figure 1. Body weight gain and glucose homeostasis in 5aR1-deficient (KO) mice and their wild-type controls after an HFD and administration
of A-348441 for 10 wk. Mice were fed an HFD or HFD plus A-348441. A-348441 ameliorated the increase in body weight gain in the (A) wild-
type but not (B, C) KO mice. (D–F) A-348441 did not significantly affect glucose levels in either genotype in response to GTTs but (G–I) had an
overall effect of ameliorating the increase in insulin levels (P 5 0.004). After 9 wk of experimental diet, (J) A-348441 had lowered the fasting
glucose in the wild-type mice only but (K) had ameliorated the increase in fasting insulin in both genotypes. KO mice overall had (I) higher
insulin and (L) hepatic triglyceride levels than the wild-type mice. Data are presented as the mean 6 SEM and by the individual genotype for
clarity, with analysis of all data by two-way ANOVA followed by the Sidak post hoc test ($P , 0.05 vs matched genotype receiving the HFD; n 5
8 to 11 per group). For overall ANOVA: *P , 0.05; **P , 0.01; ***P , 0.001. NS, not significant.
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Figure 2. Body weight and glucose homeostasis in C57BL/6 mice after dutasteride and A-348441 administration for 4 wk. C57BL/6 mice were
fed an HFD, HFD plus A-348441, HFD plus dutasteride, or HFD plus dutasteride plus A-348441 diet. A-348441 ameliorated the increased body
weight in both (A) mice fed the HFD alone and (B) mice fed the HFD plus dutasteride. (C) Mice consuming the HFD plus dutasteride
had increased body weight gain vs the mice consuming the HFD alone. (D–F) Glucose tolerance was not changed by dutasteride or A-348441
administration. A-348441 lowered the increased insulin levels induced by (G) the HFD alone and (H) in combination with dutasteride during a GTT.
(I) Dutasteride increased the insulin levels compared with mice consuming the HFD alone. A-348441 (J) had no effect on fasting glucose but (K)
normalized the increased fasting insulin caused by dutasteride combined with the HFD. (L) With a HFD, an overall effect was found for dutasteride
to increase hepatic triglyceride levels; however, A-348441 did not ameliorate this increase. Data are presented as the mean 6 SEM and stratified by
5aR status for clarity, with analysis of all data using two-way ANOVA at each point, followed by the Sidak post hoc test ($P , 0.05 vs HFD;
#P , 0.05 vs HFD plus dutasteride; n 5 8 to 12 per group; NS, not significant). For overall ANOVA: *P , 0.05; **P , 0.01; ***P , 0.001.
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The transcript abundance of genes involved in bile
acid signaling was also investigated. A-348441 lowered
Cyp7a1 mRNA abundance and increased Shp abun-
dance compared with the HFD (Fig. 3C). Dutasteride
alone also lowered Cyp7a1 mRNA abundance but
not Shp. A-348441 administered in combination with
dutasteride had no further effect on Cyp7a1 transcript
abundance compared with dutasteride administration
alone.
Hepatic insulin signaling was unaffected by
A-348441 administration
A-348441 did not alter the total protein levels of IR,
IRS2, AKT, or GSK-3b in the liver (Fig. 4A–4C).
A-348441 lowered Gys2 transcript levels only in the
presence of dutasteride. Although dutasteride decreased
Fas mRNA levels, it had little effect on other hepatic
metabolic transcripts (Fig. 3B). A-348441 treatment in-
creased the transcript abundance of Insr, Irs1, Ppargc1a,
and Fatp2, with a trend (P 5 0.07) toward greater Irs2
mRNA transcripts (Fig. 3B). When administered in
combination with dutasteride, A-348441 lowered the
transcript abundance of Gys2 only.
To better assess insulin signaling, we gave a subset
of mice in each of the treatment groups a bolus of
insulin after a 4-hour fast and collected tissue 15
minutes later. However, no changes were observed in
pSer473AKT and pSer9 GSK-3b signaling in the liver
(Fig. 4D and 4E).
Discussion
Deficiency or inhibition of 5aR1 predisposes men and
mice to insulin resistance and fatty liver (4, 7–9).
However, because 5aR1 can metabolize multiple ste-
roids, notably both glucocorticoids and androgens, it has
been unclear which hormone plays the more crucial role
in the phenotype. Rodents with deficiency in 5aR1 de-
veloped hyperinsulinemia and hepatic steatosis even after
androgen levels were decreased through castration (4),
implicating glucocorticoids as the key hormone involved.
Because 5aR1 is highly expressed in the liver, an organ
crucial to metabolic balance, and glucocorticoid levels in
this tissue are approximately doubled in 5aR1KO mice
(4), we hypothesized that the predisposition to insulin
resistance and fatty liver after 5aR1 deficiency was due
Table 2. Indexes of Metabolism in C57BL/6 Mice Fed HFD, With or Without A-348441 and/or Without
Dutasteride
Variable HFD
HFD 1
A-348441
HFD 1
Dutasteride
HFD 1
Dutasteride 1
A-348841
P Value
Effect of
Dutasteride
Effect of
A-348441 Interaction
Total weight gain, g 5.71 6 0.37 3.18 6 0.25a 7.03 6 0.52a 2.13 6 0.42b 0.73 , 0.001 0.005
Tissue weight, %
body weight
Omental adipose 0.049 6 0.003 0.036 6 0.003 0.069 6 0.006a 0.043 6 0.008b 0.010 , 0.001 0.195
Liver 4.89 6 0.08 4.71 6 0.12 5.16 6 0.12 4.56 6 0.28 0.704 0.016 0.187
Gonadal adipose 3.28 6 0.17 2.32 6 0.19a 3.46 6 0.17 2.07 6 0.18 0.838 , 0.001 0.249
Perinephric adipose 0.99 6 0.05 0.56 6 0.06a 0.99 6 0.06 0.51 6 0.07 0.726 , 0.001 0646
Mesenteric adipose 1.46 6 0.09 0.97 6 0.07a 1.56 6 0.09 1.04 6 0.05 0.354 , 0.001 0.844
Subcutaneous
adipose
1.53 6 0.09 1.02 6 0.06a 1.85 6 0.13 1.37 6 0.15b 0.004 , 0.001 0.934
Quadriceps muscle 1.24 6 0.03 1.24 6 0.04 1.17 6 0.03 1.29 6 0.03 0.734 0.098 0.092
Interscapular adipose 0.38 6 0.03 0.42 6 0.03 0.44 6 0.03 0.32 6 0.02b 0.507 0.184 0.013
Prostatec 0.049 6 0.005 NC 0.024 6 0.004a 0.034 6 0.003a NA NA NA
Biochemistry
Corticosterone, nM 86.23 6 10.9 106.6 6 23.4 32.69 6 3.9a 88.34 6 22.8 0.035 0.027 0.29
Plasma TGA, mmol/L 2.03 6 0.14 1.56 6 0.13a 2.07 6 0.12 1.76 6 0.13 0.37 0.008 0.57
Fasting NEFA, mM 2.13 6 0.11 1.98 6 0.15 2.08 6 0.01 1.54 6 0.15b 0.15 0.048 0.25
DNEFA, mM (0–15 min
of GTT)
1.11 6 0.11 0.98 6 0.16 1.36 6 0.15 0.89 6 0.13 0.61 0.08 0.31
Mice were fed the HFD, HFD 1 A-348441, HFD 1 dutasteride, or HFD 1 dutasteride 1 A-348441 for 4 wk.
Data presented as mean 6 SEM and compared using two-way ANOVA with Sidak post hoc tests.
Abbreviations: NA, not applicable; NC, not collected; TGA, triglycerides.
aP , 0.05 vs HFD alone.
bP , 0.05 vs HFD plus dutasteride.
cProstate weight was compared using one-way ANOVA: P 5 0.002; n 5 8 to 12 per group.
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Figure 3. Response of hepatic transcripts to A-348441 in C57BL/6 mice after 4 wk of experimental diet. mRNA abundance was quantified for
Nr3c1, Per1, Gilz, Sgk, Insr, Irs1, Irs2, Ppara, Pparg, Ppargc1a, Srebf1, Pepck, Gys2, Fatp2, Fatp5, Angpt12, Fas, Cyp7a1, and Shp. (A) Among
glucocorticoid-sensitive genes, dutasteride increased Per1 and lowered Sgk, although A-348441 had no effect. Dutasteride also lowered Fas
mRNA, and A-348441 increased transcript abundance for Insr, Irs1, and Ppargc1a. (B) When administered in combination with dutasteride,
A-348441 lowered Gys2 transcript levels. Both dutasteride and A-348441 lowered Cyp7a1 abundance, but (C) only A-348441 alone increased
Shp transcript levels compared with the HFD. Data are presented as mean 6 SEM and analyzed using two-way ANOVA, followed by Sidak post
hoc test ($P , 0.05 vs HFD; #P , 0.05 vs HFD plus dutasteride). For overall ANOVA: *P , 0.05 for effect of dutasteride, n 5 8 (HFD plus
dutasteride plus A-348441); n 5 10 (HFD plus dutasteride); n 5 12 (HFD and HFD plus A-348441) per group.
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to an increase in glucocorticoid action in the liver.
Using A-348441, a liver-selective hepatic GR antagonist,
we demonstrated in two models of 5aR1 deficiency,
5aR1KO mice and administration of dutasteride (a dual
5a-reductase inhibitor), that glucocorticoids contribute
to the phenotype.
Figure 4. Response of hepatic insulin signaling proteins to A-348441 in C57BL/6 mice. Total protein levels of (A) hepatic IR, IRS2, (B) AKT, and
(C) GSK-3b did not change in response to administration of A-348441. Phosphorylation status of (D) hepatic pSer473AKT and (E) hepatic
pSer9GSK-3b after insulin stimulation did not change in response to the addition of A-348441. Data are presented as mean 6 SEM and were
analyzed using the Student t test. *P , 0.05 vs HFD, n 5 6 (HFD); n 5 12 (HFD plus A-348441) per group.
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To test this hypothesis, we initially used a genetic
approach using 5aR1KO mice. These are bred from a
mixed genetic background (3), and the differences in
metabolic parameters between 5aR1KO mice and their
littermate controls develop slowly with consumption
of a high-fat diet (4, 9). The intervention with A-348441
was begun at 12 weeks of age for 10 weeks during the
decline in metabolic health. At this point, 5aR1KOmice
consuming a high-fat diet had increased insulin levels
and a greater insulin response during GTT compared
with their littermate controls. However, as expected,
differences in weight were not yet observed [this aspect
of the phenotype requires 6 months to manifest (4, 9)].
The predisposition to fatty liver in 5aR1KO mice
compared with their littermate controls was also al-
ready evident during this shorter period and before
overt changes in body weight between the genotypes
was observed.
The outcome of treatment with A-348441 in the
wild-type mice was similar to that observed in the fa/fa
rats (13, 14), with improved insulin sensitivity and
attenuation of weight gain. However, hepatic steatosis
was unresponsive to hepatic GR antagonism. Pre-
viously, genetic disruption of hepatic GR in a db/db
background had attenuated hepatic triglyceride accu-
mulation (33). Likewise, amplification of hepatic gen-
eration of glucocorticoids by overexpression of 11b-
hydroxysteroid dehydrogenase 1 exacerbated steatosis
(34). However, the lack of change is in agreement with
previous work from Macfarlane et al. (35). They
showed that systemic glucocorticoid blockade with
RU486 did not ameliorate excess liver fat in patients
with type 2 diabetes mellitus (35). The beneficial met-
abolic changes resulting from A-348441 were less
marked in the 5aR1KO mice than in their littermate
controls. Although administration of A-348441 atten-
uated the excess weight gain induced by the HFD in the
littermate control mice, this was unaffected in the
5aR1KO mice. In terms of glucose disposal, A-348441
reversed the hyperinsulinemia to a similar extent be-
tween the 5aR1KO mice and their littermate controls.
Again, hepatic steatosis caused by the HFD was un-
responsive to intervention, and the 5aR1KO mice
maintained higher liver fat levels than their littermate
controls with both diets. This was supported by the fact
that A-348441 did not lower the transcript abundance
of Fatp2 nor Fatp5 in the liver.
Given that the overall phenotype of the 5aR1KO was
improved but remained different from that of the wild-
type mice, these observations suggest that GR activation
plays a role in HFD-induced metabolic dysfunction on
this mixed genetic background but do not support the
hypothesis that it is solely glucocorticoid mediated,
unless insufficient drug had been administered, which we
believe unlikely. Had excess GR activation been solely
responsible, the difference between genotypes would
have been negated. Equivalent doses of RU486 to the
dose of A-348441 used in our study and common in
mouse models would be expected to achieve concen-
trations in the blood well in excess of those of cortico-
sterone (;100 nM) and, hence, unlikely to be limiting in
the liver (36, 37).
To gain further insight, a hepatic-selective GR an-
tagonism was pursued in a second model, that of
pharmacological inhibition with dutasteride, to better
reflect the clinical therapeutic scenario. The 5aR1KO
mice have a life-long deficiency in steroid metabolism,
including during development, and might have un-
dergone compensatory changes in steroid hormone
action and metabolism. In a clinical setting, 5aR in-
hibition generally starts later in middle-age adults.
Dutasteride, a dual 5aR inhibitor, was administered to
C57BL/6 mice, a strain predisposed to become obese,
hyperglycemic, and hyperinsulinemic owing to a nat-
urally occurring deletion in nicotinamide nucleotide
transhydrogenase (38). The C57BL/6 mice were glucose
intolerant and hyperinsulinemic after only 3 weeks of a
HFD; thus, this shorter period for the study was chosen,
matching the insulin increment in wild-type mice in the
previous experiment. The ability of 5aR inhibition to
adversely affect metabolism was apparent after 4 weeks
of treatment, reminiscent of studies in humans (4, 7).
Specifically, dutasteride exacerbated the weight gain,
increased the fasting insulin and insulin response to a
GTT, and induced hepatic steatosis in mice fed a high-
fat diet (4).
Just as with the wild-type controls of 5aR1KO mice,
the HFD-fed C57BL/6 mice treated with A-348441
alone demonstrated an improved metabolic phenotype.
The exacerbation of metabolic dysfunction by dutas-
teride was also prevented by A-348441, highlighting a
substantial role of hepatic glucocorticoids. The weight
gain was normalized to that of the chow-fed mice, and
the insulin response to a glucose challenge and plasma
triglycerides levels were all decreased. Moreover, the
white adipose depots were reduced in weight. Systemic
benefits might have been caused by hemocrine effects of
hepatic metabolic mediators, instead of direct effects
from the liver-selective drug. Other studies have dem-
onstrated manipulation of metabolic signals in the liver
such as FOXO1 and IR, as well as PI3K activity, can
indirectly affect the adipose tissue mass and systemic
insulin sensitivity (39). However, hepatic steatosis was
again not affected by hepatic GR antagonism, rein-
forcing the suggestion of a different etiology. Previous
studies have shown excess steatosis induced by
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pharmacological inhibition of 5aRs was also not re-
versed by castration, which suggests androgens alone
are also not the sole cause (4). Either a complex in-
terplay between glucocorticoids and androgens un-
derpins the liver steatosis (40) or alternative hormonal
pathways are involved. Nevertheless, we found most
aspects of the observed adverse metabolic phenotype
were responsive to GR blockade, suggesting that excess
hepatic glucocorticoid action plays a substantial role in
mediating many of the metabolic effects of dutasteride.
To further confirm the contribution of increased hepatic
glucocorticoid levels to changes in insulin sensitivity
and hepatic steatosis, dutasteride could be adminis-
trated to liver-specific GR knockout mice consuming a
high-fat diet.
To gain insight into the potential mechanism
responding to hepatic GR antagonism, hepatic transcript
abundance of the genes involved in insulin signaling and
the lipid metabolism were studied. The level of Nr3c1
(GR) mRNA was unaffected by the drug. Per1 mRNA
was studied as a known GR-responsive transcript. The
levels of Per1 were elevated by dutasteride but were not
suppressed after GR antagonism. Very few changes in
hepatic transcripts that might explain the phenotypic
changes were seen in response to GR antagonism, with
only some limited increase in genes associated with in-
sulin signaling such as Insr, Irs1, and Ppargc1a and a
small reduction in Gys2. However, a similar lack of
regulation of genes involved in gluconeogenesis or
lipid metabolism was observed when hepatic glucocor-
ticoid ligand availability was suppressed in mice with
liver-selective disruption of 11b-hydroxysteroid dehy-
drogenase 1 (41). Protein expression from the insulin
signaling pathway was also explored under insulin
stimulation; however, A-348441 had no effect on the
total or phosphorylated state of these proteins in the liver
(42, 43). Further studies using insulin clamps would
permit greater insight, and a greater difference might be
observed if the tissues were collected after a longer du-
ration of the HFD and A-348441.
Given that hemocrine mechanisms might under-
pin the improved phenotype, it is important to con-
sider the tissue selectivity of the antagonist. The
drug had been developed to attenuate hepatic GR
stimulation. Predosing with A-348441 antagonized
glucocorticoid-induced upregulation of hepatic tyrosine
aminotransferase activity by 79% and suppressed
glucocorticoid-induced hepatic glycogen formation by
59% (13). Furthermore, compared with RU486, a
systemic GR antagonist, A-348441 had substantially
less effects in nonhepatic tissues (e.g., it was 12-fold less
potent in preventing glucocorticoid-induced upregula-
tion of glutamine synthetase in L6 skeletal muscle
myocytes and 15-fold less potent in a glucocorticoid-
stimulated model of adipocyte differentiation in 3T3-L1
cells) (13). This highly liver-selective profile avoided
adverse effects on the hypothalamic pituitary adrenal
axis incurred through systemic actions or central GR
antagonism. In line with previous studies, we were able
to recapitulate that A-348441 did not affect the cir-
culating concentrations of corticosterone, suggesting
that negative feedback via GR within the brain was
unaffected by the presence of an antagonist, suggesting
minimal circulating levels (13).
GR is the most likely target for the drug; however,
because it is a conjugate of RU486 and cholic acid,
A-348441 is hepato-selective through the presence of a
bile acid. Bile acids can modulate insulin signaling
pathways via nuclear hormone receptors such as farne-
soid X receptor-a (FXRa) and GR (44, 45). It was
thought unlikely that A-348441 would have off-target
effects on the bile acid pathway, because the Kd for
binding of cholic acid to FXRa is exceedingly high
(36 mM vs a Kd of 0.27 nM for A-348441 to GR) (12)
and not anticipated with the given doses. However, we
found that A-348441 loweredCyp7a1 and increased Shp
mRNA abundance. Nonetheless, it is likely that the ef-
fects of GR and FXRa are linked—hepatic GR can
regulate systemic bile acid homeostasis, with glucocor-
ticoids inhibiting the transcriptional activity of FXR (45,
46). Furthermore, SHP is a corepressor of the gluco-
corticoid receptor (47); increased mRNA of Shp would
still have the end result of decreased GR action. Cyp7a1
and Shp mRNA abundance in mice fed dutasteride was
not significantly different from that of the mice given
dutasteride plus A-348441. Altogether, A-348441 might
influence hepatic bile acid signaling; however, the effects
of A-348441 in ameliorating the adverse phenotype
caused by dutasteride were not through the same pathways.
Had A-348441 lowered androgen levels and activation of
the androgen receptor, this would have confounded our
interpretation. However, we found no evidence of this
(e.g., a lack of reduction in prostate weight).
In conclusion, most, but not all, of the adverse met-
abolic effects of diet-induced obesity brought about by
inhibition of 5aR1 with dutasteride can be reversed by
liver-selective GR antagonism. Our data support a
substantial role for increased hepatic GR activation in the
adverse metabolic phenotype observed after pharmaco-
logical inhibition and a contributory role after genetic
disruption of 5aR1. However, the signaling pathways
underpinning the changes were elusive. A-348441
proved a useful tool to dissect the role of liver GR in
regulating the metabolism and has revealed that many of
the consequences of a high-fat diet in animal models, with
the crucial exception of steatosis, can be reversed by
doi: 10.1210/en.2019-00236 https://academic.oup.com/endo 2071
D
ow
nloaded from
 https://academ
ic.oup.com
/endo/article-abstract/160/9/2061/5518336 by U
niversity of N
ew
castle user on 16 D
ecem
ber 2019
targeting hepatic GR. The results of the present study
have consolidated the hypothesis that men receiving dual
5aR inhibitors are exposed to challenges to theirmetabolic
health. Concomitant administration of therapies that at-
tenuate glucocorticoid action, such as 11b-hydroxysteroid
dehydrogenase 1 inhibitors (48, 49) might prove to be of
benefit.
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